Showing results (431-440 of 561) with videos related to

Sort By:
Pageof 57
Journal of Surgical Oncology|August 17, 2021
The role of surgery after prolonged primary chemotherapy for advanced oesophageal adenocarcinomaMohamed S Aboul-Enein, William Knight, Wahyu Wulaningsih, et al.
Blood|September 2, 2020
Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphomaPhilippe Armand, Ann Janssens, Giuseppe Gritti, et al.
Gut|August 24, 2017
Mapping genetic vulnerabilities reveals BTK as a novel therapeutic target in oesophageal cancerIrene Yushing Chong, Lauren Aronson, Hanna Bryant, et al.
International Journal of Radiation Oncology, Biology, Physics|November 15, 2016
Positron Emission Tomography/Computed Tomography Assessment After Immunochemotherapy and Irradiation Using the Lugano Classification Criteria in the IELSG-26 Study of Primary Mediastinal B-Cell LymphomaLuca Ceriani, Maurizio Martelli, Maria K Gospodarowicz, et al.
European Journal of Cancer (Oxford, England : 1990)|July 6, 2019
The A.L.A.N. score identifies prognostic classes in advanced biliary cancer patients receiving first-line chemotherapyMassimiliano Salati, Francesco Caputo, David Cunningham, et al.
Oncotarget|June 11, 2016
Reduced genomic tumor heterogeneity after neoadjuvant chemotherapy is related to favorable outcome in patients with esophageal adenocarcinomaAskar Obulkasim, Bauke Ylstra, Hendrik F van Essen, et al.
The Lancet. Oncology|August 9, 2017
Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trialDerek Alderson, David Cunningham, Matthew Nankivell, et al.
British Journal of Haematology|November 28, 2024
Quality of life in advanced-stage, asymptomatic, non-bulky follicular lymphoma treated with rituximab shows significant improvement compared with watchful-waitingMaria A V Marzolini, Wendi Qian, Laura Clifton-Hadley, et al.
The Lancet. Haematology|April 12, 2016
Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 studySandy Amorim, Anastasios Stathis, Mary Gleeson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 15, 2016
Effect of Pathologic Tumor Response and Nodal Status on Survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy TrialElizabeth C Smyth, Matteo Fassan, David Cunningham, et al.
Pageof 57